Chen Suen - Academia.edu (original) (raw)

Uploads

Papers by Chen Suen

Research paper thumbnail of 225 Molecular targets of interest to the NCI PREVENT cancer preclinical drug development program

European Journal of Cancer

Research paper thumbnail of Proton pump inhibitor omeprazole suppresses carcinogen induced colonic adenoma progression to adenocarcinoma in F344 rat

Cancer Prevention Research

Research paper thumbnail of A phase II randomized placebo‐controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance

Research paper thumbnail of Abstract 4983: Intermittent dosing regimens of naproxen and aspirin inhibit azoxymethane-induced rat colon adenoma progression to adenocarcinoma and carcinoma invasion

Research paper thumbnail of A phase IIa randomized placebo-controlled trial of pomegranate fruit extract/POMx in subjects with clinically localized prostate cancer undergoing active surveillance

Journal of Clinical Oncology

285 Background: Due to its high prevalence and often indolent natural history, prostate cancer(PC... more 285 Background: Due to its high prevalence and often indolent natural history, prostate cancer(PC) active surveillance(AS) is an ideal setting for chemoprevention. Studies assessing pomegranate and its extracts have shown promising anti-proliferative and pro-apoptotic effects in cell lines and animal models and a single-arm clinical trial of pomegranate fruit extract(PFE) reported an increase in PSA doubling time(PSADT) during AS. The primary objective of this trial was to assess the effect of PFE supplementation on plasma levels of Insulin-like Growth Factor-1(IGF-1). Secondary objectives addressed PSA doubling time(PSADT), tumor volume on end-of-study(EOS) biopsy and plasma and prostate tissue biomarkers. Methods: Men with organ-confined favorable-risk PC on AS were randomly assigned to receive PFE 1,000 mg(n=15) or placebo(n=15) once daily for twelve months. Prostate biopsies were performed at study entry and upon completion of the one-year intervention. Tissue biomarkers were as...

Research paper thumbnail of Combination of erlotinib and naproxen employing pulsatile or intermittent dosing profoundly inhibits urinary bladder cancers

Cancer Prevention Research

Research paper thumbnail of Intermittent dosing regimens of aspirin and naproxen inhibit azoxymethane-induced colon adenoma progression to adenocarcinoma and invasive carcinoma

Cancer Prevention Research

Research paper thumbnail of Targeting cholecystokinin‐2 receptor for pancreatic cancer chemoprevention

Research paper thumbnail of Abstract 2730: Exceptional activity of ARN-509 (apalutamide) in prostate cancer prevention in rats

Prevention, Early Detection, and Interception

Research paper thumbnail of Abstract 5079: Targeting cholecystokinin-2 receptor (CCK2R) for pancreatic ductal adenocarcinoma prevention in p48Cre/+-LSL-KrasG12D/+mice model

Prevention, Early Detection, and Interception

Research paper thumbnail of Abstract 4989: Efficacy of erlotinib and/or naproxen when administered by intermittent dosing schedules in the prevention of chemically induced urinary bladder cancers

Research paper thumbnail of Abstract 1250: Evaluation of the prevention by pioglitazone/metformin of ER-positive and ER-negative mammary cancers occurring in rodents on a high-fat diet

Research paper thumbnail of Lack of chemopreventive effects of P2X7R inhibitors against pancreatic cancer

Oncotarget, Jan 17, 2017

Pancreatic cancer (PC) is an almost uniformly lethal disease with inflammation playing an importa... more Pancreatic cancer (PC) is an almost uniformly lethal disease with inflammation playing an important role in its progression. Sustained stimulation of purinergic receptor P2X7 drives induction of NLRP inflammasome activation. To understand the role of P2X7 receptor and inflammasome, we performed transcriptomic analysis of p48Cre/+-LSL-KrasG12D/+ mice pancreatic tumors by next generation sequencing. Results showed that P2X7R's key inflammasome components, IL-1β and caspase-1 are highly expressed (p < 0.05) in pancreatic tumors. Hence, to target P2X7R, we tested effects of two P2X7R antagonists, A438079 and AZ10606120, on pancreatic intraepithelial neoplasms (PanINs) and their progression to PC in p48Cre/+-LSL-KrasG12D/+ mice. Following dose optimization studies, for chemoprevention efficacy, six-week-old p48Cre/+-LSL-KrasG12D/+ mice (24-36/group) were fed modified AIN-76A diets containing 0, 50 or 100 ppm A438079 and AZ10606120 for 38 weeks. Pancreata were collected, weighed, a...

Research paper thumbnail of Abstract 5260: NGS Transcriptome analysis of colon adenocarcinomas treated with individual and combination of aspirin and omeprazole

Research paper thumbnail of Abstract 5246: Effects of bazedoxifene either alone or in combination with letrozole in the prevention of chemically induced mammary cancers

Research paper thumbnail of Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women

Expert Review of Clinical Pharmacology, 2016

Research paper thumbnail of Safety and preclinical efficacy of aerosol pioglitazone on lung adenoma prevention in A/J mice

Cancer prevention research (Philadelphia, Pa.), Jan 19, 2016

Pioglitazone is a PPARγ agonist commonly prescribed for the clinical treatment of diabetes. We so... more Pioglitazone is a PPARγ agonist commonly prescribed for the clinical treatment of diabetes. We sought to expand its use to lung cancer prevention in a benzo[a]pyrene (B[a]P) mouse model with direct lung delivery via inhalation. Initially we conducted inhalational toxicity experiments with 0, 15, 50, 150, and 450 μg/kg body weight/day pioglitazone in 40 A/J mice. We examined the animals for any physical toxicity and bronchoalveolar lavage fluids for inflammatory and cytotoxicity markers. Doses up to and including 450 μg/kg bw/day failed to demonstrate toxicity with aerosol pioglitazone. For chemoprevention experiments, A/J mice were randomized to treatment groups of inhaled doses of 0, 50, 150, or 450 µg/kg bw/day pioglitazone one week or eight weeks after the last dose of B[a]P. For the early treatment group we found up to 32% decrease in lung adenoma formation with 450 µg/kg bw/day pioglitazone. We repeated the treatments in a second late stage experiment and found up to 44% decrea...

Research paper thumbnail of Abstract 2604: Chemoprevention of colorectal cancer by LFA-9, a novel dual mPGES-1/5-LOX inhibitor: safer approaches to chemoprevention

Research paper thumbnail of Abstract 5255: Lack of chemopreventive effects of dietary P2×7R inhibitors against pancreatic cancer in p48Cre/+-LSL-KrasG12D/+ mice

Research paper thumbnail of Celecoxib alters the intestinal microbiota and metabolome in association with reducing polyp burden

Cancer prevention research (Philadelphia, Pa.), Jan 18, 2016

Treatment with celecoxib, a selective COX-2 inhibitor, reduces formation of premalignant adenomat... more Treatment with celecoxib, a selective COX-2 inhibitor, reduces formation of premalignant adenomatous polyps in the gastrointestinal tracts of humans and mice. In addition to its chemopreventive activity, celecoxib can exhibit anti-microbial activity. Differing bacterial profiles have been found in feces from colon cancer patients compared with that of normal subjects. Moreover, preclinical studies suggest that bacteria can modulate intestinal tumorigenesis by secreting specific metabolites. In the current study, we determined whether celecoxib treatment altered the luminal microbiota and metabolome in association with reducing intestinal polyp burden in mice. Administration of celecoxib for 10 weeks markedly reduced intestinal polyp burden in APCMin/+ mice. Treatment with celecoxib also altered select luminal bacterial populations in both APCMin/+ and wildtype mice including decreased Lactobacillaceae and Bifidobacteriaceae as well as increased Coriobacteriaceae. Metabolomic analysi...

Research paper thumbnail of 225 Molecular targets of interest to the NCI PREVENT cancer preclinical drug development program

European Journal of Cancer

Research paper thumbnail of Proton pump inhibitor omeprazole suppresses carcinogen induced colonic adenoma progression to adenocarcinoma in F344 rat

Cancer Prevention Research

Research paper thumbnail of A phase II randomized placebo‐controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance

Research paper thumbnail of Abstract 4983: Intermittent dosing regimens of naproxen and aspirin inhibit azoxymethane-induced rat colon adenoma progression to adenocarcinoma and carcinoma invasion

Research paper thumbnail of A phase IIa randomized placebo-controlled trial of pomegranate fruit extract/POMx in subjects with clinically localized prostate cancer undergoing active surveillance

Journal of Clinical Oncology

285 Background: Due to its high prevalence and often indolent natural history, prostate cancer(PC... more 285 Background: Due to its high prevalence and often indolent natural history, prostate cancer(PC) active surveillance(AS) is an ideal setting for chemoprevention. Studies assessing pomegranate and its extracts have shown promising anti-proliferative and pro-apoptotic effects in cell lines and animal models and a single-arm clinical trial of pomegranate fruit extract(PFE) reported an increase in PSA doubling time(PSADT) during AS. The primary objective of this trial was to assess the effect of PFE supplementation on plasma levels of Insulin-like Growth Factor-1(IGF-1). Secondary objectives addressed PSA doubling time(PSADT), tumor volume on end-of-study(EOS) biopsy and plasma and prostate tissue biomarkers. Methods: Men with organ-confined favorable-risk PC on AS were randomly assigned to receive PFE 1,000 mg(n=15) or placebo(n=15) once daily for twelve months. Prostate biopsies were performed at study entry and upon completion of the one-year intervention. Tissue biomarkers were as...

Research paper thumbnail of Combination of erlotinib and naproxen employing pulsatile or intermittent dosing profoundly inhibits urinary bladder cancers

Cancer Prevention Research

Research paper thumbnail of Intermittent dosing regimens of aspirin and naproxen inhibit azoxymethane-induced colon adenoma progression to adenocarcinoma and invasive carcinoma

Cancer Prevention Research

Research paper thumbnail of Targeting cholecystokinin‐2 receptor for pancreatic cancer chemoprevention

Research paper thumbnail of Abstract 2730: Exceptional activity of ARN-509 (apalutamide) in prostate cancer prevention in rats

Prevention, Early Detection, and Interception

Research paper thumbnail of Abstract 5079: Targeting cholecystokinin-2 receptor (CCK2R) for pancreatic ductal adenocarcinoma prevention in p48Cre/+-LSL-KrasG12D/+mice model

Prevention, Early Detection, and Interception

Research paper thumbnail of Abstract 4989: Efficacy of erlotinib and/or naproxen when administered by intermittent dosing schedules in the prevention of chemically induced urinary bladder cancers

Research paper thumbnail of Abstract 1250: Evaluation of the prevention by pioglitazone/metformin of ER-positive and ER-negative mammary cancers occurring in rodents on a high-fat diet

Research paper thumbnail of Lack of chemopreventive effects of P2X7R inhibitors against pancreatic cancer

Oncotarget, Jan 17, 2017

Pancreatic cancer (PC) is an almost uniformly lethal disease with inflammation playing an importa... more Pancreatic cancer (PC) is an almost uniformly lethal disease with inflammation playing an important role in its progression. Sustained stimulation of purinergic receptor P2X7 drives induction of NLRP inflammasome activation. To understand the role of P2X7 receptor and inflammasome, we performed transcriptomic analysis of p48Cre/+-LSL-KrasG12D/+ mice pancreatic tumors by next generation sequencing. Results showed that P2X7R's key inflammasome components, IL-1β and caspase-1 are highly expressed (p < 0.05) in pancreatic tumors. Hence, to target P2X7R, we tested effects of two P2X7R antagonists, A438079 and AZ10606120, on pancreatic intraepithelial neoplasms (PanINs) and their progression to PC in p48Cre/+-LSL-KrasG12D/+ mice. Following dose optimization studies, for chemoprevention efficacy, six-week-old p48Cre/+-LSL-KrasG12D/+ mice (24-36/group) were fed modified AIN-76A diets containing 0, 50 or 100 ppm A438079 and AZ10606120 for 38 weeks. Pancreata were collected, weighed, a...

Research paper thumbnail of Abstract 5260: NGS Transcriptome analysis of colon adenocarcinomas treated with individual and combination of aspirin and omeprazole

Research paper thumbnail of Abstract 5246: Effects of bazedoxifene either alone or in combination with letrozole in the prevention of chemically induced mammary cancers

Research paper thumbnail of Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women

Expert Review of Clinical Pharmacology, 2016

Research paper thumbnail of Safety and preclinical efficacy of aerosol pioglitazone on lung adenoma prevention in A/J mice

Cancer prevention research (Philadelphia, Pa.), Jan 19, 2016

Pioglitazone is a PPARγ agonist commonly prescribed for the clinical treatment of diabetes. We so... more Pioglitazone is a PPARγ agonist commonly prescribed for the clinical treatment of diabetes. We sought to expand its use to lung cancer prevention in a benzo[a]pyrene (B[a]P) mouse model with direct lung delivery via inhalation. Initially we conducted inhalational toxicity experiments with 0, 15, 50, 150, and 450 μg/kg body weight/day pioglitazone in 40 A/J mice. We examined the animals for any physical toxicity and bronchoalveolar lavage fluids for inflammatory and cytotoxicity markers. Doses up to and including 450 μg/kg bw/day failed to demonstrate toxicity with aerosol pioglitazone. For chemoprevention experiments, A/J mice were randomized to treatment groups of inhaled doses of 0, 50, 150, or 450 µg/kg bw/day pioglitazone one week or eight weeks after the last dose of B[a]P. For the early treatment group we found up to 32% decrease in lung adenoma formation with 450 µg/kg bw/day pioglitazone. We repeated the treatments in a second late stage experiment and found up to 44% decrea...

Research paper thumbnail of Abstract 2604: Chemoprevention of colorectal cancer by LFA-9, a novel dual mPGES-1/5-LOX inhibitor: safer approaches to chemoprevention

Research paper thumbnail of Abstract 5255: Lack of chemopreventive effects of dietary P2×7R inhibitors against pancreatic cancer in p48Cre/+-LSL-KrasG12D/+ mice

Research paper thumbnail of Celecoxib alters the intestinal microbiota and metabolome in association with reducing polyp burden

Cancer prevention research (Philadelphia, Pa.), Jan 18, 2016

Treatment with celecoxib, a selective COX-2 inhibitor, reduces formation of premalignant adenomat... more Treatment with celecoxib, a selective COX-2 inhibitor, reduces formation of premalignant adenomatous polyps in the gastrointestinal tracts of humans and mice. In addition to its chemopreventive activity, celecoxib can exhibit anti-microbial activity. Differing bacterial profiles have been found in feces from colon cancer patients compared with that of normal subjects. Moreover, preclinical studies suggest that bacteria can modulate intestinal tumorigenesis by secreting specific metabolites. In the current study, we determined whether celecoxib treatment altered the luminal microbiota and metabolome in association with reducing intestinal polyp burden in mice. Administration of celecoxib for 10 weeks markedly reduced intestinal polyp burden in APCMin/+ mice. Treatment with celecoxib also altered select luminal bacterial populations in both APCMin/+ and wildtype mice including decreased Lactobacillaceae and Bifidobacteriaceae as well as increased Coriobacteriaceae. Metabolomic analysi...

Log In